All AbMole products are for research use only, cannot be used for human consumption.
Reparixin is a noncompetitive allosteric inhibitor of IL-8 (CXCL8) activation of CXCR1 and CXCR2 chemokine receptors with IC50 of 1 and 100 nM, respectively. Reparixin effectively decreased systolic blood pressure and increased the blood flow. Treatment with reparixin significantly counteracts secondary degeneration by reducing oligodendrocyte apoptosis, migration to the injury site of neutrophils and ED-1-positive cells.
Cell Death Dis. 2020 May 29;11(5):405.
The interaction of interleukin-8 and PTEN inactivation promotes the malignant progression of head and neck squamous cell carcinoma via the STAT3 pathway
Reparixin purchased from AbMole
Molecular Weight | 283.39 |
Formula | C14H21NO3S |
CAS Number | 266359-83-5 |
Solubility (25°C) | DMSO ≥ 25 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Related CXCR Products |
---|
Elubrixin
Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. |
VUF 11222
VUF 11222 is a CXCR3 non-peptide-like agonist. |
(±)-AMG 487
(±)-AMG 487 is a racemate of AMG 487. |
Elubrixin tosylate
Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. |
Elubrixin hydrochloride
Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.